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Simple Summary: Paclitaxel (PAC) is a widely used antitumor agent in the treatment of various
early-stage and advanced cancers, including lung cancer. While efficacious, solvent-based PAC
generally is not well tolerated and is associated with severe side effects. To overcome such limitations,
naturally occurring nanocarriers such as exosomes are attracting great interest. In this paper, we show
that tumor-targeted oral formulation of PAC, using bovine colostrum-derived exosomes, not only
enhance therapeutic efficacy against orthotopic lung cancer but also mitigate or eliminate systemic
and immunotoxicity of the conventional i.v. dosing. These data will leverage the advantages of
bovine colostrum exosomes to advance the exosome-mediated targeted oral delivery of PAC as a
therapeutic alternative to current therapies.
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung
cancer (NSCLC) is the most common type accounting for 84% of all lung cancers. Paclitaxel (PAC) is
a widely used drug in the treatment of a broad spectrum of human cancers, including lung. While
efficacious, PAC generally is not well tolerated and its limitations include low aqueous solubility,
and significant toxicity. To overcome the dose-related toxicity of solvent-based PAC, we utilized
bovine colostrum-derived exosomes as a delivery vehicle for PAC for the treatment of lung cancer.
Colostrum provided higher yield of exosomes and could be loaded with higher amount of PAC
compared to mature milk. Exosomal formulation of PAC (ExoPAC) showed higher antiproliferative
activity and inhibition of colony formation against A549 cells compared with PAC alone, and also
showed antiproliferative activity against a drug-resistant variant of A549. To further enhance its
efficacy, exosomes were attached with a tumor-targeting ligand, folic acid (FA). FA-ExoPAC given
orally showed significant inhibition (>50%) of subcutaneous tumor xenograft while similar doses of
PAC showed insignificant inhibition. In the orthotopic lung cancer model, oral dosing of FA-ExoPAC
achieved greater efficacy (55% growth inhibition) than traditional i.v. PAC (24–32% growth inhibition)
and similar efficacy as i.v. Abraxane (59% growth inhibition). The FA-ExoPAC given i.v. exceeded the
therapeutic efficacy of Abraxane (76% growth inhibition). Finally, wild-type animals treated with p.o.
ExoPAC did not show gross, systemic or immunotoxicity. Solvent-based PAC caused immunotoxicity
which was either reduced or completely mitigated by its exosomal formulations. These studies
show that a tumor-targeted oral formulation of PAC (FA-ExoPAC) significantly improved the overall
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efficacy and safety profile while providing a user-friendly, cost-effective alternative to bolus i.v. PAC
and i.v. Abraxane.
Keywords: colostrum exosomes; paclitaxel; drug delivery; lung cancer; immunotoxicity assessment
1. Introduction
Cancer is the second leading cause of death worldwide. In 2020, there were an
estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United
States [1]. More people in the U.S. (135,760) are expected to die of lung cancer in 2021
than prostate, breast and colon cancer combined [2]. Lung cancer remains the leading
cause of cancer-related deaths in the United States and worldwide. Non-small cell-lung
cancer (NSCLC) is relatively insensitive to chemotherapy and accounts for about 85% of
all lung cancer cases. Regrettably, over 80% of all patients diagnosed with NSCLC die
eventually due to the disease within five years [1,3]. Despite treatment with platinum-based
chemotherapy, new molecularly-targeted therapies and immunotherapies, the overall
survival benefit for NSCLC remains modest.
Paclitaxel (PAC) is the first- or second-line chemotherapy for the treatment of various
cancers, including lung cancer and exhibits both anti-proliferative and apoptotic effects
against cancer cells. Mechanistically, PAC interferes with the normal function of cellular
microtubule growth by binding to the β-subunits of the tubulin and locking the micro-
tubules preventing further cell division. Tubulins are the building blocks of microtubules,
which play a major role in the migration of chromosomes during anaphase of the cell
division [4]. However, the utility and clinical application of PAC has been hindered due
to its poor aqueous solubility requiring formulation in the organic solvent Cremophor EL
(CrEL) and its dose-related toxicity. For these reasons, the delivery of PAC is associated
with substantial challenges. While the use of polyoxyethylated castor oil also known as
CrEL and ethanol (50:50) overcomes the solubility problem, this solvent-based approach
is associated with severe side effects [5,6]; therefore, PAC formulations are infused over
several hours to reduce the effect of bolus dose.
To overcome these solvent-based limitations, several nanoparticle systems have been
reported for the delivery of PAC. Abraxane® is an FDA-approved nanoformulation of
PAC bound to human serum albumin that was developed to improve the toxicity profile
of solvent-based PAC. In a phase III clinical trial, Abraxane was shown to enhance the
therapeutic efficacy and pharmacokinetics compared to PAC given in CrEL [7]. However,
the i.v. infusion of the Abraxane was reported to lower the blood cell count. Besides toxicity
concerns, i.v. administration requires medical assistance, which, in turn, substantially
increases the medical costs, besides patient suffering for a long duration.
To overcome these unfavorable physicochemical and pharmacokinetic properties of
PAC, several additional delivery approaches have been attempted [8]. Toxicity limitations
of solvent-based carriers can be overcome by using nanovesicles derived from natural
sources such as milk [9,10]. Further, oral dosing of the chemotherapeutic achieved using
these nanovesicles has many advantages such as flexibility of timing and location of
administration, flexibility of drug exposure, reduction of the use of healthcare resources
and a better quality of life [11,12]. Oral chemotherapy is also good for the metronomic (anti-
angiogenic) chemotherapy [13], as it maintains a low serum level of the chemotherapeutic
for a longer time than parenteral routes.
Exosomes (Exo) or small extracellular vesicles (sEVs), as the terminology is being
debated [14], are biogenic nanocarriers (30–150 nm) with the lipid bilayer and have signif-
icant role in cell-to-cell communications. Exosomes are released from essentially all cell
types and are present in all bodily fluids like blood, urine, saliva, amniotic fluid, lymphatic
fluid and milk etc. [15,16]. Unlike other nanoparticulate systems, exosomes possess special
proteins in their membrane surface proteins that may help in the endocytosis, which, in
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turn, promotes the delivery of tethered content [17,18]. We have previously demonstrated
the utility of bovine milk as a source of exosomes for the delivery of small-molecule
drugs [19–22] and siRNA [23,24] and for the oral delivery of PAC to inhibit subcutaneous
lung tumor xenografts [19]. Biocompatibility, cost-effectiveness and abundance are some
of the hallmarks that make milk exosomes a potentially commercially viable option as a
nanodrug carrier.
In this study, we used exosomes isolated from a standardized source of bovine
colostrum powder obtained from the early lactation period as a delivery vehicle for PAC
(ExoPAC). Colostrum powder provides higher yields of exosomes than mature milk. We
have shown an overexpression of FRα and RFC in H1299 and A549 lung cancer cells; the
overexpression of the folate receptors was more pronounced in tumor tissue versus normal
lung tissue (100-fold overexpression) [24]. Here, exosomes, functionalized with folic acid
(FA) to target tumor cells, are embedded with PAC (FA-ExoPAC), and the therapeutic
efficacy of the formulation was compared with Abraxane for lung tumors grown in a
tumor microenvironment. We show that FA-ExoPAC given orally surpassed efficacy of
solvent-based PAC and matched efficacy of Abraxane; whereas, i.v. FA-ExoPAC signifi-
cantly exceeded the efficacy of Abraxane. ExoPAC formulations lacked gross, systemic and
immunotoxicity in wild-type mice.
2. Materials and Methods
2.1. Chemicals and Reagents
PAC was procured from LC laboratories, Woburn, MA, USA. XenoLight D-Luciferin,
potassium salt was purchased from PerkinElmer, (Waltham, MA, USA). BCA Protein
Assay Kit was procured from ThermoFisher Scientific (Waltham, MA, USA) and folic acid
was purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of
analytical grade.
2.2. Isolation of Exosomes
Exosomes were isolated from colostrum powder (Immunodynamics, Inc., Fennimore,
WI, USA). Briefly, colostrum powder was rehydrated in deionized water achieving a fi-
nal concentration of 5% w/v, and exosomes were isolated by sequential centrifugations
(13,000× g, 30 min; 65,000× g, 60 min; and 135,000× g, 2 h, as described [22], followed
by removal of residual non-exosomal protein by ultrafiltration. After completion of ultra-
centrifugation, the supernatant containing free drug was discarded and ExoPAC pellet
was washed with PBS. The exosome pellet was suspended in PBS (pH 7.4) and sterilized
using 0.22 µM filter. The yield of exosomes was measured by means of exosomal protein
concentration by a standard BCA protein assay kit. The exosome suspension (≤6 mg/mL)
was stored at −80 ◦C.
2.3. Exosome Characterization
The particle size, polydispersity index (PDI) and zeta potential of the exosomes were
determined by Zetasizer (Malvern Instruments Ltd., Malvern, Worcestershire, UK). Particle
numbers per milligram of exosomal protein were measured by nanoparticle tracking
analyzer (NonoView, Particle Matrix Inc., Grayslake, IL, USA). Samples were analyzed
in triplicates. The size of exosomes was confirmed by atomic force microscopy (AFM) as
described [22].
2.4. FA-Functionalization of Exosomes for Tumor Targeting
We functionalized exosomes with FA, a known tumor-targeting ligand. To stabilize
the interaction of FA with exosomal proteins in vivo, we attached FA covalently by using
activated FA. Activated FA was prepared using standard EDC (1-ethyl-3-(-3-dimethyl
aminopropyl) carbodiimide hydrochloride) and NHS (N-hydroxysuccinimide esters). Free
FA was removed using ultrafiltration. The degree of functionalization was achieved by
varying FA concentration, and FA loading was determined by releasing the FA from the
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formulation in the presence of NaOH, followed by recovery of the exosomes. The FA and
exosomal proteins were measured by spectrophotometry and BCA assay, respectively, and
percent FA loading was calculated.
2.5. Loading of PAC on Exosomes
PAC was loaded onto the exosomes as described by us previously [19], except that
exosomes used were derived from colostrum powder, the ratio of exosomes to PAC was
reduced and harvesting time of ExoPAC formulation by ultracentrifuge was reduced to
achieve higher drug loading. Briefly, PAC (dissolved in ethanol: acetonitrile; 1:1 v/v)
was mixed with exosomes (6 mg/mL in PBS), keeping the solvent concentration ≤10%.
The reaction mixture was incubated at room temperature for 30 min. The unbound PAC
was removed by centrifugation (10,000× g for 10 min) and the exosomal PAC (ExoPAC)
was collected by ultracentrifugation (135,000× g for 90 min). The resulting pellet was
suspended in PBS and filter-sterilized. The ExoPAC solution (≤6 mg/mL) was stored
at −80 ◦C.
2.6. Determination of PAC Loading
PAC loading was determined by analyzing the PAC and Exo concentrations using
ultra-performance liquid chromatography (UPLC) and BCA protein estimation kit, respec-
tively, as described [19]. Briefly, 50 µL of the ExoPAC formulation was added to 950 µL of
acetonitrile to extract the PAC and precipitate the Exo protein. The reaction mixture was
then centrifuged (10,000× g for 10 min) to separate the pellet. Supernatant was collected
separately to analyze PAC. Protein pellet was suspended in PBS and its concentration was
determined by BCA.
2.7. UPLC Analysis
UPLC Shim-Pack XR-ODS II reverse-phase column (Shimadzu; 150 × 3.0 mm i.d.,
2.2 µm) was used for the analysis of PAC. Acetonitrile and water were used as a mobile
phase with 0.75 mL/min flow rate. In a linear gradient elution, the concentration of
acetonitrile was increased from 5 to 60% (from 1.3 to 5.1 min), to 80% (from 5.1 to 7.7. min)
and 100% at 10 min and maintained till 10.9 min; the concentration was then reduced to 5%
at 12 min. PAC was detected by using PDA-UV detector at 227 nm and concentration was
calculated against the standard curve of PAC.
2.8. Mechanism of Drug Loading
Proteins in exosomes show intrinsic fluorescence due to the presence of aromatic
residues of tryptophan, tyrosine and phenylalanine. This property was utilized to deter-
mine the fluorescent quenching of exosomes due to hydrophobic interaction with different
concentration of PAC, as reported for human serum albumin [25]. Briefly, exosomes alone
(6 mg/mL) and PAC-loaded exosomes in PBS were analyzed for fluorescent signals at exci-
tation and emission wavelengths of 280 nm and 320 nm, respectively, using a SpectraMax
Spectrofluorometer. The reduction in the fluorescent signals in the presence of PAC was
calculated and suggestive that the strong hydrophobic interactions play a crucial role in
drug loading onto exosomes.
2.9. Cell Lines and Maintenance
Human lung cancer cell lines A549 were obtained from American Type Culture Collec-
tion (Manasa, VA, USA) and taxol-resistant A549TR cells were provided by Dr. Bruce Zetter
of Children’s Hospital Boston, Harvard Medical School (Boston, MA, USA). Bioware® Brite
Cell Line A549 Red-FLuc was procured from PerkinElmer, USA. Cells were cultured in
RPMI (Gibco, Waltham, MA, USA) supplemented with 10% FBS and antibiotics (peni-
cillin/streptomycin) at 37 ◦C in 5% CO2. No antibiotic solution was supplied to the
culture media.
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2.10. In Vitro Antiproliferative Activity
The effect of PAC and its exosomal formulation on cell viability was measured using
the MTT assay. Briefly, A549 and A549TR cells were plated in 96-well plates at an initial
density of 3 × 103 cells per well and treated with Exo, PAC or ExoPAC and incubated for
72 h. The cell survival was determined by MTT assay, as described [26]. Briefly, A549-LUC
cells (3 × 103 cells/well) were plated in 96-well white plates. Cells were treated with PAC
and ExoPAC at different concentrations for 72 h. Culture media were replaced with fresh
media containing luciferin (150 µg/mL). The luminescence intensity was measured using a
SpectraMax spectrophotometer.
2.11. Colony-Forming Assay
Taxol-sensitive (A549) and taxol-resistant (A549TR) cells were seeded into 6-well
tissue culture plates at a density of 500 cells/well, as described [26]. The cells were treated
with PAC or ExoPAC at different concentrations for 24 h. The drug-containing medium
was discarded and replaced with a fresh drug-free medium. After 10 d, the plates were
washed with sterile PBS, and the cells were fixed using methanol/acetic acid solution (3:1)
for 5 min and stained with 0.5% crystal violet (in methanol) for 15 min. The crystal violet
solution was carefully removed, the cells were rinsed with water and air dried at room
temperature. The number of colonies in each well was counted manually.
2.12. Animal Studies
All animals were maintained according to the Institutional Animal Care and Use
Committee guidelines (IACUC).
2.12.1. Lung Cancer Subcutaneous Xenograft
Female athymic nude (nu/nu) mice (5–6 weeks old) were procured from Harlan
(Indianapolis, IN, USA) and used to assess the antitumor efficacy. Lung tumor xenografts
were produced by subcutaneously injecting human lung A549 cells (2.5 × 106), in serum-
free media mixed with Matrigel matrix (Becton Dickinson, Bedford, MA, USA), in the left
flank of the mice. Animals were provided purified AIN93M diet and water ad libitum.
Once the average tumor size reached about 100 mm3, mice were randomized into four
groups (n = 10) and provided with oral doses of PBS, PAC, ExoPAC and FA-ExoPAC, three
times a week. The PAC doses in all the regimens were kept equal (6 mg/kg). Tumor
size, animal weights, diet intake, and overall animal health were monitored weekly. After
7 weeks of treatment, the animals were euthanized and select tissues were collected for
further analysis.
2.12.2. Lung Cancer Orthotopic Xenograft
Pilot Study
For the orthotopic lung tumor model, we first performed a pilot study to establish the
effect of doses and time on tumor growth, before initiating the tumor inhibition study. After
acclimation, female NOD/SCID mice (4–5-week old) were randomized into three groups
(n = 4) and inoculated with Bioware® Brite A549-Red-Fluc cells (1 × 106, 2 × 106, and
4 × 106 cells) in 50 µL of Matrigel mixed in serum-free media (1:1; v/v) via intrathoracic
injection using 30-gauge needles [27,28]; an untreated group served as control. Luciferase
expressions were monitored for tumor growth twice a week. The luciferase signals were
detected 15 min post-intraperitoneal injection of luciferin (120 mg/kg) by using Advanced
Molecular Imager, AMI1000.
Tumor Inhibition Study (Low Dose)
For the tumor inhibition study, groups of female NOD/SCID mice were inoculated
with A549-Red-Fluc cells (2 × 106 cells) via intrathoracic injection, as described above.
After 10 days, when the luminescence intensity reached approximately 6 × 106 photons,
animals were randomized (n = 10) and treated with i.v. PAC, i.v. Abraxane, p.o. ExoPAC,
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i.v. FA-ExoPAC or p.o. FA-ExoPAC. The i.v. doses of all regimens having PAC (6 mg/kg)
were given once a week, whereas oral doses were given three times a week. The PAC and
Abraxane were given i.v. to mimic the clinical scenario. Two additional groups were treated
with Exo and FA-Exo. The exosome concentration in all the formulations was 50 mg/kg.
Tumor Inhibition—Higher Dose
This study was patterned after the low dose study and the animals were randomized
(n = 10) and treated with PAC, Abraxane, ExoPAC and FA-ExoPAC given orally or intra-
venously, as described for the low dose study, except PAC was given initially at 4 mg/kg
for three weeks, then switched to 8 mg/kg in all the regimens; the frequency of dosing
and the exosome concentration was same as in the low-dose study. Bodyweight gains, diet
intake, and overall animal physical health were monitored weekly. At euthanasia, various
tissues were collected and imaged ex vivo. Lung, liver, and tumor tissues were collected
and stored at −80 ◦C for marker analysis.
2.12.3. Toxicity Study
Female C57BL/6 mice (5–6 weeks old) were purchased from Charles River Labo-
ratories. Animals were randomized in six groups (n = 5) and treated with vehicle, Exo
(60 mg/kg/week; oral), FA-Exo (60 mg/kg/week; oral), PAC (6 mg/kg/week; i.p.), Ex-
oPAC (9 mg/kg/week; p.o.) and FA-ExoPAC (9 and 18 mg/kg/week; p.o.). The exosome
concentration was kept constant to 60 mg/week in all the exosomal formulation-treated
groups. The drug was given three times a week in all the treatment groups and continued
for four weeks. Bodyweight, physical mobility and food intake were monitored twice a
week throughout the study. After four weeks of treatments, animals were euthanized by
CO2 asphyxiation. At the time of euthanasia, blood and the major organs were weighed
and collected for further analysis. The spleen and femur bone were collected in fresh media
to harvest the spleen and bone marrow cells.
Systemic Toxicity
Blood was collected at the time of euthanasia and hematological parameters were
analyzed using whole blood by the CellDyn 3500 hematology analyzer (Abbott laboratories,
Santa Clara, CA, USA). Serum was used to analyze the liver and kidney function enzymes,
as described [23]. Electrolyte analysis was done by using an ion-selective electrode while
other biochemical parameters were analyzed spectrophotometrically using AU640 Chem-
istry Immuno Analyzer (Beckman Coulter, Inc., Brea, CA, USA). Spleen and bone marrow
were used for immune toxicity studies described below.
Immune Cell Analysis
Immune cell quantification was performed by staining single-cell suspensions of
spleen cells with fluorescent dye-coupled antibodies to CD19 for B cells, CD5 (total T-
cells), CD4, and CD8 for T-cell subsets, F4/80, CD11b, Gr-1, to identify macrophages and
neutrophils, CD11c for dendritic cells, NK1.1 and CD49b for natural killer cells.
Bone marrow stem and progenitor cells were identified by negative staining for
lineage-specific markers using biotin-labelled antibodies to B220, CD11b, Gr-1, CD5, CD8,
Ter-119 and APC-Cy7 coupled streptavidin and positive staining for Sca-1 and c-kit. The
cells stained with fluoresceinated antibodies were analyzed using an LSR II flow cytometer
(BD BioSciences) and the data were analyzed using FlowJo software. All statistical analyses
were performed by two-way ANOVA using group A as the control group.
For cytokine assays, spleen cells were cultured with lipopolysaccharide (LPS) or anti-
CD3 antibody for 24 h in Iscove’s DMEM (IMDM) in the presence of 10% fetal calf serum.
The culture supernatants were analyzed for IL-6, IL-10, IL-2 and γ-interferon using specific
reagents obtained from R&D Biosystems (Minneapolis, MN, USA) and multiples reagent
from MesoScale using respective recombinant cytokines as standards. Data are presented
as percent control where control is the average value for spleen cells from PBS-treated mice.
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2.13. Statistical Analysis
Statistical analysis was performed with GraphPad Prism statistical software (version
4.03; La Jolla, CA, USA) using two-way ANOVA followed by a Bonferroni post-test for
xenograft studies. Data in the xenograft studies are expressed as mean ± standard error
of mean (SEM) (n = 10). Statistical significance of differences in immune cell numbers,
cytokine assays and proliferation responses between various treatments was evaluated by
an unpaired Student’s t-test. Values of p < 0.05 were considered statistically significant.
3. Results
3.1. Exosome Isolation and Characterization
Colostrum derived exosomes are lipid bilayer nanovesicles and their diameters vary
from 30–150 nm. Exosome suspension was homogenous with an average particle size
of 59 ± 1.1 nm, PDI of 0.3 ± 0.1, and zeta potential of −30.2 ± 0.1 mV, as determined
by Zetasizer and NanoView (Figure 1A); these analyses were performed after removing
PBS from the exosomes by ultrafiltration (300,000 MWCO spin filter) since the presence
of PBS increased zeta potential of the particles. Zeta view analysis of exosomes showed
0.5–1.0 × 1014 particles per mg of exosomal proteins. The size was confirmed with AFM
(Figure 1B). Exosomes isolated from colostrum showed hallmark protein markers such as
CD81, Tsg101, Alix and the anti-phagocytic protein, CD47, as described elsewhere [24].




Figure 1. Characterization and drug loading of colostrum-derived exosomes. Size, polydispersity index (PDI), and zeta 
potential (ZP) of exosomes, FA-Exo, ExoPAC and FA-ExoPAC, analyzed by Zetasizer. Data represent mean ± SD from 
three preparations (A). Analysis of exosomes and ExoPAC by atomic force microscopy (AFM) after diluting with deion-
ized water up to 10 µg/mL. For measurement, samples were placed on a silica wafer and air-dried for 30 min. AFM in 
tapping mode and aluminum-coated silicon probes were used for imaging (B). The bar diagram shows the quenching of 
autofluorescence from the exosomes following PAC loading (C). Higher quenching of fluorescence in the presence of 
higher drug load suggests a hydrophobic interaction of drug with exosomal proteins. 
3.2. Drug Loading and FA Functionalization 
Exosomes were functionalized by covalently attaching FA first, followed by loading 
of PAC. The PAC was loaded with simple mixing of drug solution with FA-functionalized 
exosome. The size of exosomes was only slightly increased (68 ± 6.3 nm from 59 ± 1.1) after 
FA conjugation. However, PAC loading increased the size modestly for both exosomes 
(89 ± 1.1 from 59 ± 1.1) and FA-exosomes (98.8 ± 4.1 from 68.1 ± 6.3). The zeta potential of 
FA-ExoPAC (-19.8 ± 0.5) was increased compared with exosomes (−30.2 ± 0.1) and ExoPAC 
(−23.3 ± 0.9) (Figure 1A,B). 
3.3. Mechanistic Understanding of Drug Loading in Exosomes 
We utilized quenching of intrinsic fluorescence of surface-bound exosomal proteins 
to determine if the PAC was surface-bound. We observed a dose-dependent decrease in 
fluorescence with an increase in PAC loading to exosomes. The percent fluorescence 
quenching was correlated with the PAC load—a drug load of 24%, 57% and 75% resulted 
in 26%, 49% and 64% fluorescence quenching, respectively (Figure 1C). These data clearly 
suggest that at least part of the drug is sequestered in the hydrophobic domains of surface-
bound exosomal proteins; however, we cannot rule out that part of the drug is in the lipid 
bilayer and/or lumen of the exosomes. 
  
. i i l i f colostr - i . i , l i i i ,
potential (ZP) of exosomes, FA-Exo, ExoPAC and FA-ExoPAC, analyzed by Zetasizer. Data represent mean ± SD from three
preparations (A). Analysis of exosomes and ExoPAC by atomic force microscopy (AFM) after diluting with deionized water
up to 10 µg/mL. For measurement, samples were placed on a silica wafer and air-dried for 30 min. AFM in tapping mode
and aluminum-coated silicon probes were used for imaging (B). The bar diagram shows the quenching of autofluorescence
from the exosomes following PAC loading (C). Higher quenching of fluorescence in the presence of higher drug load
suggests a hydrophobic interaction of drug with exosomal proteins.
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3.2. Drug Loading and FA Functionalization
Exosomes were functionalized by covalently attaching FA first, followed by loading
of PAC. The PAC was loaded with simple mixing of drug solution with FA-functionalized
exosome. The size of exosomes was only slightly increased (68 ± 6.3 nm from 59 ± 1.1)
after FA conjugation. However, PAC loading increased the size modestly for both exosomes
(89 ± 1.1 from 59 ± 1.1) and FA-exosomes (98.8 ± 4.1 from 68.1 ± 6.3). The zeta potential
of FA-ExoPAC (−19.8 ± 0.5) was increased compared with exosomes (−30.2 ± 0.1) and
ExoPAC (−23.3 ± 0.9) (Figure 1A,B).
3.3. Mechanistic Understanding of Drug Loading in Exosomes
We utilized quenching of intrinsic fluorescence of surface-bound exosomal proteins
to determine if the PAC was surface-bound. We observed a dose-dependent decrease
in fluorescence with an increase in PAC loading to exosomes. The percent fluorescence
quenching was correlated with the PAC load—a drug load of 24%, 57% and 75% resulted
in 26%, 49% and 64% fluorescence quenching, respectively (Figure 1C). These data clearly
suggest that at least part of the drug is sequestered in the hydrophobic domains of surface-
bound exosomal proteins; however, we cannot rule out that part of the drug is in the lipid
bilayer and/or lumen of the exosomes.
3.4. ExoPAC Inhibits Growth of Both Drug-Sensitive and Drug-Resistant Lung Cancer Cells
The antiproliferative effects of PAC, ExoPAC and FA-ExoPAC were determined against
drug-sensitive and drug-resistant human lung cancer cells and compared with albumin-
bound PAC (Abraxane). PAC and its exosomal formulations showed a dose-dependent cell
growth inhibition against A549 cells. FA-ExoPAC, however, showed a twofold reduction in
the IC50 values compared to PAC; the IC50 of Abraxane was similar to PAC (Figure 2A).
Exosome alone (Figure 2A) and FA-Exo (data not shown) demonstrated about 20% inhi-
bition of A549 cells. To determine if the exosomal formulation could chemosensitize the
drug-resistant cells, we tested all the formulations against taxol-resistant A549TR lung
cancer cells. PAC did not show any inhibition of the resistant cells up to 200 nM. However,
the data indicated that FA-ExoPAC was able to inhibit the growth of the drug-resistant
cells dose-dependently with the IC50 values of 12.5 nM. ExoPAC and Abraxane showed a
similar effect. (Figure 2B).
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Figure 2. ExoP liferation of drug-sensitive and drug-resi tant cells. (A) Drug-sensitive
(A549) and drug-resistant (A549TR) cells wer treated with Exo, a
compared with Abraxane. Antiproliferative activity was determined by MTT assay after 72 h.
Exosomal PAC dose-dependently inhibited the proliferation of drug-sensitive A549 (A) and drug-
resistant A549TR cells (B).
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3.5. Colony Formation Assay
To validate the observed antiproliferative effects, we investigated the potential effects
of PAC and ExoPAC on the replicative ability of drug-sensitive (A549) and its drug-resistant
variant (A549TR) using colony formation assay (Figure 3A,B). Similar to the MTT data,
while PAC showed 65% inhibition of colony formation at 6.25 nM, ExoPAC had over 90%
inhibition at the same dose. Interestingly, the effect of PAC (25–100 nM) was minimal on
the resistant cells, while ExoPAC had significant inhibition starting from 25 nM. As ex-
pected, ExoPAC showed dose-dependent inhibition of colony formation against both A549
(Figure 3A; Supplementary Figure S1) and A549TR (Figure 3B; Supplementary Figure S2)
cells; ExoPAC inhibited colony formation in both cell lines greater than PAC alone.




Figure 3. Exosomal PAC inhibited colony formation in NSCLC cells. Representative images showing the colony formation 
assay in drug-sensitive A549 (A) and drug-resistant A549TR (B) cells. Lung cancer cells were seeded (500 cells/well) in a 
six-well plate and incubated with different concentrations of PAC and ExoPAC. After 10 days, developed colonies were 
fixed, stained and counted manually. While PAC was effective, only against drug-sensitive cells (A1,B1), ExoPAC shows 
dose-dependent inhibition of colony formation of both sensitive and resistant cells (A2,B2). Statistical analysis was per-
formed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
3.6. Antitumor Efficacy Following Oral Administration of ExoPAC 
3.6.1. Subcutaneous Lung Tumor Xenografts 
We determined the antitumor efficacy of ExoPAC and FA-ExoPAC using athymic 
nude mice bearing subcutaneous A549 xenografts and compared them with PAC. There 
was no difference in the body weight or diet consumption, suggesting no gross toxicity 
due to PAC or ExoPAC. Compared to untreated control, PAC (6 mg/kg) showed about 
30% but statistically insignificant inhibition of the tumor growth. However, ExoPAC (6 
mg/kg PAC and 50 mg exosomal proteins/kg) showed a significant (45%; p < 0.05) growth 
inhibition at the end of the study (Figure 4). FA-ExoPAC at the same dose was even more 
effective (54%; p < 0.05) with the growth inhibition occurring as early as five weeks after 
the treatment (Figure 4). 
 
Figure 3. Exosomal PAC inhibited colony formation in NSCLC cells. Representative images showing the colony formation
assay in rug-sensitive 549 ( ) and drug-resistant A549TR (B) cells. Lung cancer cells were seeded (500 cells/well)
in a six-well plate a d incubated with different concentrations of PAC and ExoP C. After 10 days, developed colonies
were fixed, stai ed and counted manually. While PAC was effective, only against drug-sensitive cells (A1,B1), ExoPAC
shows dose-dependent inhibition of colony formation of both sensitive and resistant cells (A2,B2). Statistical analysis was
performed using the Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
3.6. Antitumor Efficacy Following Oral Administration of ExoPAC
3.6.1. Subcutaneous Lung Tu or Xenografts
e determined the antitumor efficacy of ExoPAC and FA-ExoPAC using athymic nude
mice bearing subcutaneous A549 xenografts and compared them with PAC. There was no
difference in the body weight or diet c nsumption, suggesting no gross toxicity due to
PAC r ExoPAC. Compared to untreated control, PAC (6 mg/kg) showed ab ut 30% b t
statistically in ignifica t inhibition of the tumor growth. However, ExoPAC (6 mg/kg PAC
and 50 mg exosomal proteins/kg) sh wed a significant (45%; p < 0.05) growth inhibiti n at
the end f the study (Figure 4). FA-ExoPAC at the same dose was even more effective (54%;
p < 0.05) with the growth nhibition occurring as early as five w eks after the tr atment
(Figure 4).
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Figure 4. Antitumor activity against subcutaneous xenografts. Following inoculation with A549 cells,
nude mice were treated with oral gavage three times a week with PAC (6 mg/kg bw), ExoPAC and
FA-ExoPAC (6 mg PAC and 50 mg Exo protein/kg bw). Data represent average ± SD of means
(n = 8). Statistical analysis was performed using the Student’s t-test. * p < 0.05; ** p < 0.01.
3.6.2. Orthotopic Lung Tumor Xenografts
We first established an orthotopic lung tumor model in a pilot study using Bioware®
Brite A549 Red-FLuc lung cancer cells. Live animal imaging showed the biolumines-
cence signals from lung tumors (Figure 5A); tumor growth was dose- and time-dependent
(Figure 5A). The tumors could be detected as early as 10–12 days after tumor cell inocula-
tion, with nearly exponential growth. After four weeks, animals inoculated with different
cell numbers showed a dose-dependent increase in bioluminescence signals. Based on the
tumor growth and expected tumor size, we used 2 × 106 cells in efficacy studies.
In an efficacy study, two doses of PAC (6 mg/kg and 8 mg/kg) were tested. Figure 5B
shows the data from the low-dose study; i.v. PAC showed 32% inhibition of tumor growth
whereas p.o. FA-ExoPAC showed a somewhat higher growth inhibition (39%), although
the difference was not statistically significant; the nonfunctionalized formulation (ExoPAC)
showed only a slight inhibition (18%). However, FA-ExoPAC administered i.v. resulted in
significantly higher growth inhibition (70%; p < 0.001) matching the efficacy of i.v. Abraxane
(62%; p < 0.001).
The data presented in Figure 5(C1,C2) demonstrates significant tumor growth inhi-
bition in the following order: i.v. FA-ExoPAC (76%; p < 0.001) > p.o. FA-ExoPAC (55%,
p < 0.001) ≈ i.v. Abraxane (59%, p < 0.001) > p.o. ExoPAC (36%, p < 0.05) > i.v. PAC (24%) >
p.o. FA-Exo (9%).
Clearly, oral FA-ExoPAC far exceeded the efficacy of i.v. PAC and, in fact, matched the
efficacy elicited by i.v. Abraxane; i.v. FA-ExoPAC exceeded the efficacy of i.v. Abraxane.
Dose-optimization studies are warranted to identify the most efficacious oral doses and
frequency of FA-ExoPAC formulation. At the completion of the study, we observed that
animals treated with i.v. FA-ExoPAC (6 and 8 mg/kg) did not exhibit any mortality,
while about 42% of the animals died in solvent-based i.v. PAC and 30% in control groups.
Importantly, ExoPAC-treated animals also showed a significantly improved overall health
index compared to PAC or untreated controls (Supplementary Figure S3).
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3.7. Assessment of Toxicity Due to PAC and ExoPAC
3.7.1. Systemic Toxicity
For the analysis of the potential toxicity of PAC, exosomes and ExoPAC, wild-type
C57BL/6 mice were treated for 28 days and assessed for gross and systemic toxicity. We
observed no difference in the body weight, diet intake and physical wellness of treated
versus control animals. We analyzed the levels of liver enzymes (aspartate transaminase,
alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, amylase,
and lipase) in the serum of animals treated either with PAC, exosomes or ExoPAC. PAC
significantly changed the levels of amylase and total bilirubin. These effects were not
evident with ExoPAC suggestive of hepatoprotective role when PAC was embedded in
exosomes. Similarly, toxicity caused by PAC in kidney function tests and hemopoietic
parameters was mitigated by its formulations in exosome (Tables 1 and 2).
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Table 1. Effect on biochemical profile (systemic toxicity) following 28 days exposure to Exo, PAC and
ExoPAC in C57BL/6 mice.
Parameter Control Exo PAC ExoPAC FA-ExoPAC
Liver Profile
AST (SGOT) 400 ± 220 343 ± 102 381 ± 80 314 ± 73 423 ± 83
ALT (SGPT) 39.7 ± 20.0 56.0 ± 19.5 51.8 ± 20.2 42.0 ± 4.9 53.2 ± 17.6
Alk Phosphatase 62.8 ± 62.2 89.2 ± 17.4 10.5 ± 4.9 14.0 ± 9.9 63.0 ± 49.5
GGT 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
Amylase 378 ± 164 523 ± 17 987 ± 606 * 525 ± 28 476 ± 80
CPK 1044 ± 499 1488 ± 596 1231 ± 541 1030 ± 393 1313 ± 278
Total Bilirubin 0.6 ± 0.4 0.1 ± 0.0 * 0.1 ± 0.0 * 0.5 ± 0.3 # 0.6 ± 0.3 ##
Kidney Function Test
BUN 16.6 ± 4.1 19.6 ± 0.9 12.6 ± 3.1 16.8 ± 3.8 15.4 ± 3.1
Creatinine 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
BUN/CreatRatio 83.1 ± 20.5 98.0 ± 4.5 63.0 ± 15.7 84.0 ± 19.2 77.0 ± 15.7
Phosphorus 13.0 ± 4.8 18.5 ± 4.6 10.4 ± 0.6 10.1 ± 0.8 10.1 ± 0.8
Calcium 7.5 ± 1.7 11.0 ± 0.8 *** 8.7 ± 0.6 8.4 ± 0.5 8.1 ± 0.4
Magnesium 5.0 ± 2.0 4.2 ± 0.3 3.8 ± 0.8 3.9 ± 0.4 4.2 ± 0.5
Sodium 120.5 ± 23.5 150.2 ± 5.7 * 137.2 ± 6.3 135.8 ± 6.3 131.6 ± 5.9
Potassium 17.5 ± 15.5 9.2 ± 0.8 9.0 ± 2.2 10.4 ± 1.3 12.5 ± 1.9 #
NA/K Ratio 10.6 ± 5.6 16.4 ± 1.8 * 16.0 ± 2.6 13.6 ± 1.9 10.8 ± 2.5 #
Chloride 115.4 ± 13.9 111.8 ± 8.0 121.8 ± 3.8 123.2 ± 3.8 117.6 ± 5.9
Total Protein 7.9 ± 3.7 6.2 ± 0.5 5.6 ± 1.3 6.4 ± 0.6 6.7 ± 0.6
Albumin 4.9 ± 2.1 3.7 ± 0.3 2.9 ± 0.8 3.8 ± 0.6 4.2 ± 0.5 #
Globulin 2.8 ± 1.0 2.4 ± 0.3 2.7 ± 0.6 2.7 ± 0.3 2.5 ± 0.4
A/G Ratio 1.8 ± 0.4 1.6 ± 0.2 1.1 ± 0.1 ** 1.5 ± 0.4 1.7 ± 0.3 ##
Cholesterol 343 ± 317 142 ± 20 148 ± 44 157 ± 31 204 ± 47
Triglyceride 60.6 ± 29.8 84.6 ± 14.3 93.8 ± 16.9 * 84.0 ± 9.9 64.4 ± 10.4 #
Glucose 147.1 ± 40.4 89.8 ± 66.8 109.2 ± 17.6 154.0 ± 7.0 # 159.6 ± 26.8 ##
Female C57BL/6 mice (5–6 weeks old) were provided control diet (AIN 93M) and water ad libitum and treated
with colostrum-derived exosomes (60 mg/kg, b. wt.) by oral gavage, i.p. PAC (8 mg/kg) and ExoPAC and
FA-ExoPAC (8 mg/kg PAC and 60 mg/kg exosome) for 28 days, three times a week. At euthanasia, blood was
collected and analyzed using an automated AU640 Chemistry Analyzer by Antech diagnostics. Data represent
average ± SD of four animals. Statistical analysis was performed by the Student t-test. Asterisks represent
comparison to control while # represents a comparison to PAC group. *, p-value <0.05; **, p < 0.01; ***, p < 0.001;
#, p-value <0.05; ##, < 0.01.
Table 2. Effect on hematological parameters (systemic toxicity) following 28-day exposure to exo-
somes, PAC and ExoPAC in C57BL/6 mice.
Parameter Control Exo PAC ExoPAC FA-ExoPAC
WBC 7.4 ± 1.6 4.3 ± 1.9 ** 7.7 ± 0.9 5.3 ± 1.7 *,# 4.6 ± 2.0 *,#
RBC 9.2 ± 0.4 9.0 ± 0.4 7.8 ± 0.5 *** 8.0 ± 2.3 8.5 ± 0.9
HGB 14.5 ± 0.6 14.7 ± 0.5 12.8 ± 0.4 *** 12.4 ± 4.3 13.3 ± 1.7
HCT 45.7 ± 1.4 46.5 ± 2.1 37.2 ± 2.6 *** 38.6 ± 11.9 40.4 ± 4.2 **
MCV 49.3 ± 1.7 51.3 ± 0.5 47.4 ± 1.1 48.0 ± 1.9 47.2 ± 0.8 *
MCH 15.8 ± 0.9 16.3 ± 0.2 16.5 ± 0.7 15.1 ± 1.7 15.6 ± 0.9
MCHC 32.0 ± 2.1 31.8 ± 0.5 34.6 ± 1.9 31.6 ± 2.8 33.0 ± 1.9
Platelet Count 856 ± 111 829 ± 145 891 ± 131 674 ± 260 570 ± 202 **,#
Neutrophils 9.7 ± 3.8 13.5 ± 6.1 30 ± 11.6 *** 8.8 ± 2.8 ## 10.8 ± 2.4 ##
Bands 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Lymphocytes 87.1 ± 3.1 82.3 ± 4.2 66 ± 12.6 *** 87.6 ± 3.0 ## 84.8 ± 3.8 ##
Monocytes 1.1 ± 1.3 3.0 ± 2.3 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
Eosinophils 2.0 ± 1.2 1.3 ± 0.5 3.0 ± 1.2 2.6 ± 0.9 3.4 ± 1.7
Basophils 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Absolute
Neutrophils 688.1 ± 208.5 561.3 ± 314.7 2345 ± 1026 ** 453.2 ± 170.1
## 479.6 ± 221.1 ##
Absolute
Lymphocytes 6519 ± 1563 3546 ± 1686 5008 ± 1082 4664 ± 1573 3942 ± 1731 *
Absolute
Monocytes 44.0 ± 17.0 115.8 ± 79.4 76.6 ± 8.7 53.0 ± 16.8
# 46.0 ± 19.5 #
Absolute
Eosinophils 152.0 ± 101.4 52.3 ± 24.8 * 231 ± 105 130.0 ± 37 132.0 ± 22
Female wild-type C57BL/6 mice (5–6 weeks old) were provided control diet (AIN 93M) and water ad libitum and
treated with colostrum-derived exosomes (60 mg/kg, b. wt.) by oral gavage, i.p. PAC (8 mg/kg) and ExoPAC and
FA-ExoPAC (8 mg/Kg PAC and 60 mg/kg exosome) for 28 days, three times a week. At euthanasia, blood was
collected and analyzed using an automated AU640R Chemistry Analyzer by Antech diagnostics. Data represent
average ± SD of four animals. Statistical analysis was performed by the Student t-test. *, p < 0.05; **, p < 0.01;
***, p < 0.001 in comparison to control group. #, p < 0.05 and ##, p < 0.01 in comparison to PAC group.
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3.7.2. Immunotoxicity
Single cell suspensions of splenic and bone marrow cells were prepared and viable
cells were quantified by trypan blue exclusion. No significant differences were found in
the total cell numbers of splenic as well as bone marrow cells (Figure 6A,B) upon any of
the treatments. Next, splenic cells were stained with multiple fluorochrome-conjugated
antibodies specific to B cells (CD19), total T-cells (CD5), T-cell subsets (CD4, CD8) and
were analyzed by flow cytometry. Overall percentages of the different lymphocyte subsets
were not significantly different between control and ExoPAC or FA-ExoPAC treatment
groups. Interestingly there were small reductions in total CD5+ and CD8+ T-cells in the
spleen after treatment with PAC alone but these reductions were abrogated when PAC
was provided as ExoPAC or FA-ExoPAC. On the other hand (Figure 7B). PAC caused a
significant increase (p < 0.001) of macrophages (F4/80), neutrophils (CD11b+Gr-1+) and
dendritic cells (CD11c+) compared to control, which were mitigated by the use of exosomal
formulations. Natural killer cells (NK1.1+) were unaffected irrespective of treatment
(Figure 7C). However, in the analysis of bone marrow cells, there was no difference in
neutrophils (CD11b+Gr-1+) and B cells (B220) by any treatment (Figure 7C).
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Figure 6. Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and
FA-ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Live splenic (A) and bone marrow
(B) cell counts were performed by trypan blue exclusion.
Stem and progenitor (LSK or LIN-Sca-1+cKit+) cells were highly increased by treat-
ment with PAC (p < 0.001), whereas this increase was not found with ExoPAC formulations
suggesting that exosomal formulation could mitigate the toxicity associated with PAC
(Figure 7D). Splenic cells were induced to proliferate by treating with different stimulants
for 72 h, which is an important requirement for effective immune response to tumor cells
or pathogens. Cells were pulsed with 3H-thymidine for 4 h, then, cells were harvested
and the incorporation of radioactivity was quantified using a beta-plate counter. PAC
treatment showed a lower T-cell proliferation and a lower T-cell independent B-cell prolif-
eration induced by LPS (p < 0.01). However, exosomal formulation mitigated these adverse
effects. There was no significant difference in the αCD40 treatment, which represents a
T-cell-dependent B-cell proliferation response (Figure 7E).
In order to assess cytokine response, splenic cells were treated with different stimu-
lants for 24 h. Sups were collected and MesoScale analysis (V-PLEX of 6 cytokines) was
performed. LPS was used for B-cell and macrophage response and αCD3+αCD28 was
used for T-cell response (Figure 8). We observed increase in almost all cytokines (except
IL-2, which was decreased) in response to PAC treatment, which was mitigated with the
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exosome formulations suggesting protection of PAC-induced immunotoxicity by exosomal
formulations (Figure 8).




Figure 7. Potential immunotoxicity of PAC and FA-ExoPAC. Female C57BL/6 mice were treated with Exo, PAC and FA-
ExoPAC for four weeks. At euthanasia, spleen and bone marrow cells were collected. Splenic cells were stained with 
multiple fluorochrome-conjugated antibodies. Samples were run using LSRII cytometer and data was analyzed by FlowJo 
software. Effect of treatment was analyzed on B cells, total T-cells, T helper cells, and cytotoxic T-cells (A), macrophages, 
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4. Discussion
PAC is an antineoplastic chemotherapeutic drug that is routinely used as the first-
or second-line chemotherapeutic in the treatment of a broad spectrum of human can-
cers, including lung cancer. As with many other chemo drugs, PAC exhibits poor oral
bioavailability; hence, it is administered intravenously. To increase bioavailability, sev-
eral drug delivery formulations of PAC have been developed, including nanoparticle
albumin-bound (Abraxane®), liposomal (Lipusu®), polymeric micelles (Genexol® PM),
polymeric-drug conjugates (Xyotax™/OPAXIO) and an injection concentrate for nanodis-
persion (Taclantis™/Bevetex®), as reviewed by Chor et al. [8]. Clinical translatability of
these nanoformulations was impeded due to various factors like toxicity, scalability and
cost. In addition to cremophor-based PAC, Abraxane is the only formulation of PAC ap-
proved by the FDA to date while the remaining formulations, also as i.v. therapeutics, are
currently in clinical trials at various stages. In a randomized multinational phase 3 study
(NCT02594371) lead by Athenex Inc., an oral formulation of PAC and Encequidar was
evaluated in women with metastatic breast cancer. This combination therapeutic showed
improved progression-free survival and overall survival compared to i.v. PAC in breast
cancer patients [29]. Encequidar, although not systemically absorbed, is an inhibitor of
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multidrug resistance efflux pump P-glycoprotein that increases the oral bioavailability of
PAC by preventing the efflux of PAC from intestinal epithelial cells in the GI tract. While
oral PAC/encequidar carried less risk of neuropathy and alopecia compared to i.v. PAC,
higher risk for GI and neutropenia adverse events was found [30]. These results exemplify
the potential of oral PAC for the treatment of cancer while mitigating, in-part, toxicity
of bolus i.v. dosing, however, the oral PAC formulation used in these clinical studies
lacks specificity.
The primary objective of this study is to develop a tumor-targeted oral formulation
of PAC (FA-ExoPAC) to improve the overall efficacy and safety profile while providing
a user-friendly, cost-effective alternative to bolus i.v. PAC. Exosomes provide a nontoxic
scalable and cost-effective approach to drug delivery. Exosomes are biogenic nanocarriers
and have been shown by us and others to deliver both small and macromolecules to
the tumor site [19,21–24]. Most of the current exosomal delivery technologies rely on
harvesting exosomes from cells grown in high-density bioreactors. Mendt et al. [31]
reported production of 10–15 × 1012 exosomes per bioreactor culture. In comparison,
exosomes isolated from milk or colostrum are abundant in a readily available source, bovine
milk, which dominates commercial production and is estimated to be 85% of worldwide
milk consumption [32]. Bovine milk contains abundant exosomes (239 ± 9.6 mg exosomal
protein or 33 × 1016 particles/L) [22]. The abundance of exosomes is further increased in
bovine colostrum. Clearly, bovine milk/colostrum contains several orders of magnitude
higher amounts of exosomes/L than media from high-density bioreactors.
The generally recognized safety of colostrum powder combined with high exosome
yield makes it a biocompatible source for cost-effective, large-scale production of exosomes.
In these studies, bovine colostrum powder derived exosomes showed small uniform
distribution of size, approximating 60 nm, which only slightly increased (13%) following
the covalent attachment of the tumor-targeting ligand FA while a modest increase (approx.
30%) in exosomal size was observed following the loading of PAC. This modest increase in
exosomal size and our observed fluorescent quenching of exosome surface-bound proteins
due to hydrophobic interaction with increasing concentrations of PAC could be attributed
to sequestration of PAC by the hydrophobic domains of the exosomal surface-bound
proteins; however, we cannot rule out that part of the drug is in the lipid bilayer and/or
lumen of the exosomes.
Cancer cells develop resistance to PAC through several mechanisms like initiating
the efflux pump, DNA mutations and changes in microtubule dynamics. In our in vitro
antiproliferative and colony-forming studies, we noted while PAC is effective against the
drug-sensitive cells, its exosomal formulations showed significant activity even against
drug-resistant cells, suggesting a role for exosomes in preventing the efflux of PAC. The
present study suggests that lung cancer drug resistance towards PAC could be avoided
by using exosomal formulation. We have previously shown that the growth of normal
epidermal keratinocytes (HEKn) and Beas-2B epithelial cells was unaffected by milk exo-
somes [21,22]. In the present study we showed that ExoPAC did not disturb the immune
homeostasis which was affected by PAC alone in altering some immune cell subsets. Also,
ExoPAC, unlike PAC did not alter the cytokine production or growth response of various
immune cells further attesting to near absence of any immunotoxicity.
Tumor-targeted drug delivery approaches have attracted extensive attention due
to their ability to achieve higher drug accumulation in tumor site and reduce off-target
effects. Under physiological conditions, reduced form of folates transports into the cells
via reduced folate carrier (RFC) through an anion-exchange mechanism. After entering
the cell, folate plays a crucial role in biosynthesis of building blocks of DNA synthesis,
methylation and repair [33]. The other form of folate entry into the cell is through folate
receptor (FR). There are four isoforms of FR (FRα, FRβ, FRγ and FRδ) identified in humans.
In cancer cells, the expression of FRα covers the entire cell surface due to loss of its
polarized cellular location. FRα, the target of FA, is present at low levels in normal tissues
but it is overexpressed in majority of NSCLCs and in lung adenocarcinomas [34]. Our
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data show >100-fold higher expression levels in lung tumors versus normal lung. We
also showed that FA-Exo-AF750 resulted in significantly higher tumor accumulation of
exosomes compared with nonfunctionalized Exo-AF750 [24]. Thus, the limited expression
and restricted distribution pattern of this receptor make it attractive for targeting lung
tumors [35]. Once FA or RFC binds to the FR receptor, the total complex enters into the
cells via the process of endocytosis. In this context, FA serves as a feasible option to direct
ExoPAC to cancer cells. In this study, FA was covalently attached to exosomes to enhance
the specificity of ExoPAC. Since FA is not retained in the kidneys, no significant toxicities
have been observed in rodent models or humans with FRα-targeted agents [35–37].
Oral dosing of chemotherapeutics offers many advantages—including flexibility of
timing, location of administration, flexibility of drug exposure, reduction of the use of
the healthcare resources for in-patient and ambulatory-patient care services, and a better
quality of life [11,12]. However, due to the poor GI absorption and hepatic first-pass
effect, bolus doses of PAC and other chemotherapeutics are required for efficacy and likely
contribute to overall toxicity.
It is evident from our previous study that ExoPAC using exosomes from bovine
milk exhibits enhanced anticancer response versus free PAC against lung cancer cells and
efficiently inhibits the lung cancer subcutaneous xenografts [19]. In this study, first we show
that given orally, ExoPAC and FA-ExoPAC, using exosomes isolated from bovine colostrum
powder, demonstrate much higher activity compared to free PAC in subcutaneous lung
cancer xenografts, followed by efficacy studies using an orthotopic model to mimic relevant
tumor microenvironment. Our previous studies demonstrate that exosomes maintain their
integrity in gastrointestinal pH and the release of PAC was consistent at wide ranges
of pH (5, 5.8 and 6.8) resembling physiological conditions of the body, suggesting that
ExoPAC formulations are stable in the harsh environment of GI and produce higher activity
compared to free PAC.
As per our previous studies, colostrum exosomes express CD47 protein marker along
with other hallmark exosomal proteins on their surface, which enhances the circulatory
half-life of the exosomal drug formulations [24]. Further, FA functionalization on exosomes
leads to trafficking to tumor site due to the presence of folate receptors (FR-α) and reduced
folate receptors (RFC) on tumor cells. At the tumor site, exosomes are internalized in the
cancer cells through several mechanisms like endocytosis, phagocytosis, micropinocytosis
and/or fusion with cellular plasma membrane [38–41]. After entering the cell cytoplasm,
exosomes directly release their payloads or undergo lysosomal digestion to release the
drug contents [42]. In this study, we postulated that FA-ExoPAC releases PAC inside the
cancer cells either through direct release or by the lysozyme-mediated digestion, which
was clearly demonstrated by its in vivo antitumor response against subcutaneous and
orthotropic lung cancer xenografts.
The orthotopic xenograft models represent a clinically relevant tumor model with
respect to the tumor’s primary site, microenvironment and metastasis [43,44]. These
models are further improved with the advent of imaging techniques, which help in the
measurement of internally implanted orthotopic tumors. In this study, using an orthotopic
model, we demonstrate that FA-ExoPAC given either i.v. or p.o. has much greater efficacy
compared to PAC i.v. and that for the higher dose study, FA-ExoPAC given orally produced
efficacy similar to i.v. Abraxane. Noteworthy is that when used i.v., FA-ExoPAC produced
significantly higher antitumor activity compared to Abraxane, suggesting the potential of
exosome-based drug formulation for the management of cancer. The enhanced activity of
FA-ExoPAC could be due to tumor targeting, slow release of PAC from the exosomes and
intrinsic ability of exosomes to inhibit the cancer cells [21].
Clinical translatability of new drugs or nanoformulations are often limited due to
toxicity concerns at various stages of drug discovery and development. While efficacious,
PAC is generally not well tolerated and its limitations include low solubility, and signif-
icant toxicity associated with both the drug and the solvent (Cremophor EL), including
hypersensitivity reactions, bronchospasms, hypotension, hematological toxicity, periph-
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eral sensory neuropathy, myalgia, arthralgia and alopecia [8,45]. We have demonstrated
FA-ExoPAC clearly enhanced therapeutic efficacy of PAC diminishing the dose-related
toxicity issues. Our previous toxicity study reports establish milk exosomes as nontoxic
and nonimmunogenic [19]. The present study using colostrum exosomes further sup-
ports lack of PAC-related gross, systemic and immune toxicity concerns when used in an
exosomal formulation.
5. Conclusions
In summary, our findings have potential clinical implications for the management of
advanced non-small cell lung cancer and potentially other cancers routinely treated with
PAC. We showed that: (i) an abundance of exosomes in standardized bovine colostrum
powder displays high PAC loading, and enhanced tumor targeting with FA-functionalized
exosomes; (ii) PAC in exosomal formulation exhibits strong activity against both drug-
sensitive (A549) and drug-resistant (A549TR) lung cancer; (iii) ExoPAC administered orally
inhibit both subcutaneous and orthotopic lung tumors, and the efficacy is enhanced when
FA-functionalized exosomes are used; (iv) p.o. FA-ExoPAC surpassed the efficacy of i.v.
PAC and matched efficacy of i.v. Abraxane in one study; (v) i.v. FA-ExoPAC exceeded
efficacy of i.v. Abraxane, the only FDA-approved albumin-bound nanoformulation of
PAC; and (vi) FA-ExoPAC minimally perturbed the immune homeostasis of the host, thus
eliminating potential adverse effects of PAC on the immune system. Together, these data
provide a strong rationale for the development of oral exosomal formulations of PAC as a
therapeutic alternative to current therapies.
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